Management Team

The VisionGate® management team has considerable prior-company experience in the creation of cutting-edge technologies in both pharmaceuticals and diagnostics including late stage development, commercial new product planning and new product launch:

Alan C. Nelson, PhD – Founder, Chairman & CEO

Dr. Nelson, is founder, chairman and CEO of VisionGate. He is a physicist, bioengineer and entrepreneur who developed the world’s first and only automated screening test to detect cervical cancer, marketed today as FocalPoint by Becton Dickinson. He is former Executive Director of Arizona State University’s (ASU) Biodesign Institute and has held faculty positions at ASU, University of Washington, MIT and Harvard. Dr. Nelson holds more than 100 US patents and has more than 100 peer-reviewed publications in the field of biomedical imaging.

Javier Zulueta, MD – Chief Medical Officer

Dr. Javier Zulueta is a world-renowned pulmonologist, professor and 16-year Director of Pulmonary Service at the University Clinic of Navarra, the teaching hospital of Spain’s University of Navarra School of Medicine. Dr. Zulueta led the longest ongoing lung cancer screening trial in Europe. The study is part of the International Early Lung Cancer Action Program (I-ELCAP) consortium, of which he has been the Principal Investigator since its inception in 2000. He has authored more than 100 publications in peer-reviewed journals and has been an invited lecturer at more than 100 international conferences.

Randal L. Buness, CPA, MBA – Chief Financial Officer

Mr. Buness is a senior financial executive with over 25 years of results-oriented leadership. Prior to joining VisionGate, he served as Chief Financial Officer of multiple high-growth, public and private medical and high technology companies. Most recently he served as CFO of Cayenne Medical, Inc., a medical device company that was acquired by Zimmer Biomet. His financial background includes expertise in venture capital, public stock offerings, and mergers and acquisitions. Early in his career, Mr. Buness spent ten years in public accounting at Ernst & Young and PricewaterhouseCoopers.

Michael G. Meyer, MS – Chief Technology Officer

As CTO, Mr. Meyer manages efforts among the various technical groups and provides final technical arbitration. He also supervises development of the Cell-CT™ platform and training of algorithms to compute VisionGate test results as well as the development of technical strategies to validate them. He was previously a research scientist for TriPath Imaging, Inc. (formerly NeoPath), where he supervised a variety of efforts to develop algorithms to detect rarely occurring cervical neoplasms and their precursors on Pap smear slides. Prior to TriPath, he was employed at IBM in Rochester, MN.

Greg Zick, PhD – Chief Product Officer

Mr. Zick leads all Product Development relating activities and brings over 30 years of experience in computer applications to medicine, computer systems, software development, National Science Foundation (NSF), National Institute of Health (NIH) funded research projects. Holder of six patents, Greg has led the design and development of multiple products and systems.

Jon W. Hayenga, MS – Vice President, Advanced Product Development

Mr. Hayenga has 30 years of product development experience, 22 of it in FDA-regulated industry. He has held senior engineering and management roles in previous start-up biomedical technology companies, including NeoPath, where he delivered emerging complex technology products. Before joining VisionGate, Mr. Hayenga was director of engineering at Micronics where he developed patented technologies utilizing instrumentation and micro-fluidics solutions for the biotech industry. He holds more than 30 patents and contributes at the theoretical level as well as the applied level.

Randall Mastrangelo, MBA – Vice President, Global Business Development, Commercial Strategy and Marketing

Mr. Mastrangelo provides leadership over our global business development, commercial strategy and global marketing. He has over 25 years of biopharmaceutical industry experience effectively leading both global and US commercial teams in multiple disease areas with extensive experience across a range of tumors in the oncology therapeutic area including lung cancer, chemoprevention, diagnostics strategy and nuclear medicine imaging. Since 2017 he has advanced VisionGate’s diagnostics and pharmaceuticals commercial strategy planning, marketing, and preparation for launch activities. Before joining VisionGate Mr. Mastrangelo was Global Commercial Head for IRESSA® (gefitinib) a lung cancer pharmaceutical therapy marketed in over 90 countries.


This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.

Copyright 2019 - VisionGate, Inc.